Cell Death in AMD: The Rationale for Targeting Fas.

Fas apoptosis macular degeneration necroptosis

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
25 Jan 2022
Historique:
received: 28 12 2021
revised: 18 01 2022
accepted: 21 01 2022
entrez: 15 2 2022
pubmed: 16 2 2022
medline: 16 2 2022
Statut: epublish

Résumé

Age-related macular degeneration (AMD) is a leading cause of irreversible blindness in the developed world. While great advances have been made in the treatment of the neovascular ("wet") form of the disease, there is still a significant need for therapies that prevent the vision loss associated with the advanced forms of dry, atrophic AMD. In this atrophic form, retinal pigment epithelial (RPE) and photoreceptor cell death is the ultimate cause of vision loss. In this review, we summarize the cell death pathways and their relation to RPE and retinal cell death in AMD. We review the data that support targeting programmed cell death through inhibition of the Fas receptor as a novel approach to preserve these structures and that this effect results from inhibiting both canonical death pathway activation and reducing the associated inflammatory response. These data lay the groundwork for current clinical strategies targeting the Fas pathway in this devastating disease.

Identifiants

pubmed: 35160044
pii: jcm11030592
doi: 10.3390/jcm11030592
pmc: PMC8836408
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Subventions

Organisme : NEI NIH HHS
ID : 1R42EY029625-01
Pays : United States

Références

Int Ophthalmol Clin. 2013 Fall;53(4):105-17
pubmed: 24088937
BioDrugs. 2021 May;35(3):303-323
pubmed: 33893984
J Clin Med. 2021 Jun 11;10(12):
pubmed: 34208067
Arch Ophthalmol. 2002 Nov;120(11):1435-42
pubmed: 12427055
Prog Retin Eye Res. 2013 Nov;37:114-40
pubmed: 23994436
J Neuroinflammation. 2018 Jan 12;15(1):15
pubmed: 29329580
Curr Opin Ophthalmol. 2021 May 1;32(3):294-300
pubmed: 33630787
J Neuroinflammation. 2015 Sep 22;12:179
pubmed: 26394985
Ophthalmologica. 2016;236(1):53-8
pubmed: 27287199
Cell. 1997 Feb 7;88(3):347-54
pubmed: 9039261
Trends Microbiol. 2001 Mar;9(3):113-4
pubmed: 11303500
Nat Rev Dis Primers. 2021 May 6;7(1):31
pubmed: 33958600
Methods. 2013 Jun 1;61(2):117-29
pubmed: 23473780
Invest Ophthalmol Vis Sci. 2008 Apr;49(4):1345-9
pubmed: 18385048
Arch Ophthalmol. 2005 Nov;123(11):1570-4
pubmed: 16286620
N Engl J Med. 1996 Jun 27;334(26):1717-25
pubmed: 8637518
Invest Ophthalmol Vis Sci. 2020 Apr 9;61(4):28
pubmed: 32324857
PLoS One. 2018 Aug 29;13(8):e0203337
pubmed: 30157273
Ageing Res Rev. 2015 Nov;24(Pt B):286-98
pubmed: 26369358
J Exp Med. 2000 Apr 3;191(7):1209-20
pubmed: 10748238
Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2328-33
pubmed: 16452172
Nat Immunol. 2000 Dec;1(6):489-95
pubmed: 11101870
Acta Ophthalmol. 2012 Jun;90(4):299-309
pubmed: 22112056
Arch Ophthalmol. 2004 Apr;122(4):564-72
pubmed: 15078675
Nat Rev Microbiol. 2009 Feb;7(2):99-109
pubmed: 19148178
PLoS One. 2012;7(9):e46664
pubmed: 23029562
J Immunol. 2016 Dec 15;197(12):4626-4638
pubmed: 27849168
PLoS One. 2011 Mar 29;6(3):e17659
pubmed: 21479271
J Photochem Photobiol B. 2016 Aug;161:177-83
pubmed: 27240191
Ophthalmology. 2005 Apr;112(4):533-9
pubmed: 15808240
Free Radic Biol Med. 2014 May;70:155-66
pubmed: 24440594
Arch Ophthalmol. 2007 Oct;125(10):1389-95
pubmed: 17923548
Free Radic Biol Med. 2014 Apr;69:1-14
pubmed: 24434119
Cell Death Discov. 2016 Jul 04;2:16054
pubmed: 27551542
Ophthalmic Res. 2021;64(6):888-902
pubmed: 34153966
Invest Ophthalmol Vis Sci. 2013 Jan 07;54(1):110-20
pubmed: 23221073
Mol Cell. 2013 Mar 28;49(6):1034-48
pubmed: 23434371
Nat Rev Immunol. 2013 Jun;13(6):438-51
pubmed: 23702979
Ophthalmology. 2020 Feb;127(2):186-195
pubmed: 31474439
Methods. 2008 Mar;44(3):205-21
pubmed: 18314051
J Neuroinflammation. 2019 Sep 30;16(1):184
pubmed: 31570110
Pharmaceuticals (Basel). 2018 Oct 22;11(4):
pubmed: 30360383
Invest Ophthalmol Vis Sci. 2017 Mar 1;58(3):1801-1810
pubmed: 28346613
Invest Ophthalmol Vis Sci. 2013 Mar 01;54(3):2225-37
pubmed: 23462752
Neuron. 2012 Jul 12;75(1):26-39
pubmed: 22794258
Cell. 2020 May 28;181(5):1188-1188.e1
pubmed: 32470402
Trends Immunol. 2018 Dec;39(12):1036-1053
pubmed: 30401514
Nat Chem Biol. 2005 Jul;1(2):112-9
pubmed: 16408008
Ophthalmology. 2021 Apr;128(4):576-586
pubmed: 32882310
Pharmacol Ther. 2000 Dec;88(3):333-47
pubmed: 11337030
Cell Death Differ. 2017 Oct;24(10):1799-1810
pubmed: 28708137
Cell Death Differ. 2018 Mar;25(3):486-541
pubmed: 29362479
Curr Opin Ophthalmol. 2002 Jun;13(3):171-5
pubmed: 12011686
FEBS J. 2018 Mar;285(5):809-827
pubmed: 29032605
Invest Ophthalmol Vis Sci. 2004 Dec;45(12):4563-9
pubmed: 15557468
Cell. 2012 May 25;149(5):1060-72
pubmed: 22632970
J Mol Biol. 2022 Feb 28;434(4):167378
pubmed: 34838807

Auteurs

David N Zacks (DN)

Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, MI 48105, USA.

Andrew J Kocab (AJ)

ONL Therapeutics, Inc., Ann Arbor, MI 48104, USA.

Joanne J Choi (JJ)

Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, MI 48105, USA.

Meredith S Gregory-Ksander (MS)

Department of Ophthalmology, Schepens Eye Research Institute, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA 02114, USA.

Marisol Cano (M)

Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD 21287, USA.

James T Handa (JT)

Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD 21287, USA.

Classifications MeSH